In clinical trials, tirzepatide has demonstrated dose‐dependent efficacy in people with obesity, T2D or both, in terms of glycated haemoglobin (HbA1c) level reduction and bodyweight reduction compared with placebo, GLP‐1 receptor agonists and basal insulin.11, 12. Here, INS is linked to Obesity.